Company Dossier · Health Care
Corcept Therapeutics
- Russell 1000
- MidCap 400
What Corcept Therapeutics is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $0.83 billion, up 15% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.11 billion, down 39% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.00 billion.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.17 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 24, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $56.2 million on the open market.SEC Form 4
- 423 institutional managers reported a position at June 30, 2026 (+71 on the quarter before).SEC Form 13F
- H-1B filings certified in Q1 2026: 1.U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Corcept Therapeutics yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 8, 2026Trademark
- Sep 23, 20268-KDirector or officer changeItem 5.02
- Sep 15, 2026Patent
- Jul 28, 2026Patent
- Jun 9, 2026Patent
- May 28, 20268-KDirector or officer changeItem 5.02
- May 28, 20268-KShareholder vote resultsItem 5.07
- May 26, 2026Trademark
- May 12, 2026Patent
- May 5, 2026Patent
- Mar 18, 2026Trademark
- Mar 18, 2026Trademark
- Feb 24, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- Jan 6, 2026Trademark
- Oct 14, 20258-KMaterial agreement terminatedItem 1.02
- Oct 6, 20258-KDirector or officer changeItem 5.02
- Jun 16, 20258-KShareholder vote resultsItem 5.07
- Feb 26, 202510-KAnnual report (10-K)1 risk factors added, 3 removed
- Feb 15, 202410-KAnnual report (10-K)1 risk factors added, 4 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Jazz Pharmaceuticals JAZZ | $4.6B | $1.6B | Jun 30, 2026 |
| Organon & Co. OGN | $6.1B | $0.6B | Jun 30, 2026 |
| Zoetis ZTS | $9.5B | $2.3B | Jun 30, 2026 |
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |
| Ionis Pharmaceuticals IONS | $0.9B | −$0.6B | Jun 30, 2026 |
| Repligen RGEN | $0.8B | $0.1B | Jun 30, 2026 |
| Axsome Therapeutics AXSM | $0.8B | −$0.1B | Jun 30, 2026 |